Antidepressant safety labeling impact
Executive Summary
A Medco study finds that less than 15% of patients on antidepressants receive the FDA recommended level of follow-up care in first four weeks of treatment, 18% at eight weeks and 23% at 12 weeks. The findings, which appear in the August issue of the American Journal of Managed Care, reviewed 84,500 pediatric and adult patients who started a new course of antidepressant therapy between July 2001 and September 2003. The study revealed that 66% of children and 83% of adults had no follow-up visits during the first month of treatment; FDA recommends weekly in-person visits with a health practitioner during that period. FDA required the antidepressant class to add a "black box" warning on suicidality in 2005 (1"The Pink Sheet" Jan. 17, 2005, p. 3)....
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.